David Dalvey Sells 20,000 Shares of Celcuity (NASDAQ:CELC) Stock

Celcuity, Inc. (NASDAQ:CELC) Director David Dalvey sold 20,000 shares of the business’s stock in a transaction that occurred on Tuesday, January 27th. The shares were sold at an average price of $120.03, for a total value of $2,400,600.00. Following the sale, the director owned 90,000 shares of the company’s stock, valued at approximately $10,802,700. This represents a 18.18% decrease in their position. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available at this link.

Celcuity Stock Down 2.1%

Shares of CELC traded down $2.41 during trading hours on Thursday, reaching $112.12. The stock had a trading volume of 875,073 shares, compared to its average volume of 774,929. The firm has a 50-day simple moving average of $103.64 and a 200 day simple moving average of $70.79. Celcuity, Inc. has a 12 month low of $7.57 and a 12 month high of $120.32. The company has a current ratio of 12.26, a quick ratio of 12.26 and a debt-to-equity ratio of 2.74. The company has a market capitalization of $5.19 billion, a price-to-earnings ratio of -30.55 and a beta of 0.25.

Celcuity (NASDAQ:CELC) last released its quarterly earnings data on Wednesday, November 12th. The company reported ($0.92) earnings per share for the quarter, topping the consensus estimate of ($1.05) by $0.13. Equities research analysts predict that Celcuity, Inc. will post -2.62 earnings per share for the current fiscal year.

Hedge Funds Weigh In On Celcuity

A number of large investors have recently modified their holdings of the company. Apis Capital Advisors LLC purchased a new stake in Celcuity in the third quarter worth approximately $38,334,000. UBS Group AG lifted its holdings in shares of Celcuity by 910.1% in the 3rd quarter. UBS Group AG now owns 854,483 shares of the company’s stock worth $42,211,000 after acquiring an additional 769,891 shares during the last quarter. Deerfield Management Company L.P. bought a new stake in shares of Celcuity in the 3rd quarter worth approximately $36,236,000. Alliancebernstein L.P. grew its holdings in shares of Celcuity by 2,208.6% during the 3rd quarter. Alliancebernstein L.P. now owns 652,649 shares of the company’s stock valued at $32,241,000 after purchasing an additional 624,379 shares during the last quarter. Finally, Soleus Capital Management L.P. grew its holdings in shares of Celcuity by 17.0% during the 2nd quarter. Soleus Capital Management L.P. now owns 3,011,818 shares of the company’s stock valued at $40,208,000 after purchasing an additional 437,696 shares during the last quarter. 63.33% of the stock is owned by hedge funds and other institutional investors.

Analysts Set New Price Targets

A number of research firms recently commented on CELC. HC Wainwright reissued a “neutral” rating and issued a $94.00 price target (up from $77.00) on shares of Celcuity in a research report on Monday, November 17th. Jefferies Financial Group upped their price target on Celcuity from $108.00 to $134.00 and gave the company a “buy” rating in a research report on Tuesday, December 2nd. Stifel Nicolaus lifted their price objective on shares of Celcuity from $68.00 to $115.00 and gave the company a “buy” rating in a research note on Thursday, November 13th. Weiss Ratings reissued a “sell (d-)” rating on shares of Celcuity in a report on Wednesday, January 21st. Finally, Wells Fargo & Company started coverage on Celcuity in a research note on Friday, December 12th. They set an “overweight” rating and a $126.00 price objective for the company. One investment analyst has rated the stock with a Strong Buy rating, seven have issued a Buy rating, one has assigned a Hold rating and one has given a Sell rating to the stock. According to MarketBeat, the stock has a consensus rating of “Moderate Buy” and an average price target of $105.25.

Celcuity Company Profile

Celcuity, Inc is a clinical-stage biotechnology company specializing in precision oncology diagnostics. The company develops and commercializes predictive biomarker assays designed to identify which patients are most likely to benefit from targeted cancer therapies. By integrating functional profiling of tumor cells with molecular analyses, Celcuity seeks to optimize treatment selection and improve outcomes for patients with solid tumors.

Celcuity’s proprietary platform evaluates tumor cell sensitivity to various therapeutic agents using ex vivo assays that measure DNA damage response and other critical pathways.